Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy


Alibas H., Uluc K. , Koytak P. K. , Uygur M. M. , Tuncer N., Tanridag T. , et al.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, cilt.40, ss.1365-1372, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 40 Konu: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s40618-017-0722-y
  • Dergi Adı: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Sayfa Sayısı: ss.1365-1372

Özet

Aims Acromegaly is caused by a pituitary adenoma that releases excess growth hormone (GH) and a concomitant increase in insulin-like growth factor 1 (IGF-1). Acromegaly results not only in phenotypic changes, but also in neurologic complications as peripheral neuropathy and cognitive dysfunction. This study aimed to compare depressive mood and cognitive function in patients with acromegaly and in healthy controls as well as to determine the factors underlying cognitive dysfunction in the acromegalic patients.